MINNEAPOLIS--(BUSINESS WIRE)--With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation (DBS) therapy, Medtronic, Inc. (NYSE: MDT) today announced the technology’s commercial availability throughout the United States and Europe. The single-channel Activa SC complements Medtronic’s industry-leading Activa PC and Activa RC dual-channel DBS offerings and is the latest addition to the company’s Activa portfolio of DBS systems, the most advanced DBS devices available to treat the symptoms of advanced Parkinson’s disease and essential tremor in the U.S. and Europe. The device is also approved for dystonia in Europe.
